, predicted to enable the biosynthesis of a glycosylated griseorhodin variant. Following the successful cultivation of the strain, the production of a previously uncharacterized griseorhodin, named ruskamycin, was confirmed that featured a distinctive digitoxose-substituted epoxy-spiroketal pharmacophore and exhibited antibacterial activity against Gram-positive strains.
Sowa et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: